StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.40+0.10 (+0.55%)

Close on Nov 18, 2026Market cap $1.33BP/E 9.3Yield –

Innoviva revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Innoviva's revenue for the twelve months ending Sep 30, 2026 was $438.32M, up 12.8% year over year. For fiscal 2025 it was $411.33M, up 14.7% from the year before. Over ten years it grew 22.5% a year on average. The highest annual figure on record is $411.33M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$411.33M+14.7%
FY2024Dec 31, 2024$358.71M+15.5%
FY2023Dec 31, 2023$310.46M-6.3%
FY2022Dec 31, 2022$331.34M-15.4%
FY2021Dec 31, 2021$391.87M+16.4%
FY2020Dec 31, 2020$336.79M+29.0%
FY2019Dec 31, 2019$261.02M+0.0%
FY2018Dec 31, 2018$261.00M+20.2%
FY2017Dec 31, 2017$217.22M+62.6%
FY2016Dec 31, 2016$133.57M+147.6%
FY2015Dec 31, 2015$53.95M+539.7%
FY2014Dec 31, 2014$8.43M+86.1%
FY2013Dec 31, 2013$4.53M-19.3%
FY2012Dec 31, 2012$5.61M-77.1%
FY2011Dec 31, 2011$24.51M+1.2%
FY2010Dec 31, 2010$24.22M-0.6%
FY2009Dec 31, 2009$24.37M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$106.12M-1.6%
Q2 FY2026Jun 30, 2026$119.59M+19.3%
Q1 FY2026Mar 31, 2026$97.99M+10.6%
Q4 FY2025Dec 31, 2025$114.61M+24.8%
Q3 FY2025Sep 30, 2025$107.80M+20.4%
Q2 FY2025Jun 30, 2025$100.28M+0.4%
Q1 FY2025Mar 31, 2025$88.63M+14.4%
Q4 FY2024Dec 31, 2024$91.81M+7.0%
Q3 FY2024Sep 30, 2024$89.51M+33.1%
Q2 FY2024Jun 30, 2024$99.90M+23.3%
Q1 FY2024Mar 31, 2024$77.50M+1.5%
Q4 FY2023Dec 31, 2023$85.84M+30.4%
Q3 FY2023Sep 30, 2023$67.26M+0.0%
Q2 FY2023Jun 30, 2023$80.99M-25.2%
Q1 FY2023Mar 31, 2023$76.37M-15.2%
Q4 FY2022Dec 31, 2022$65.80M-38.9%
Q3 FY2022Sep 30, 2022$67.26M-31.3%
Q2 FY2022Jun 30, 2022$108.22M+7.4%
Q1 FY2022Mar 31, 2022$90.06M+5.3%
Q4 FY2021Dec 31, 2021$107.68M+19.0%
Q3 FY2021Sep 30, 2021$97.86M+10.3%
Q2 FY2021Jun 30, 2021$100.81M+27.7%
Q1 FY2021Mar 31, 2021$85.52M+8.7%
Q4 FY2020Dec 31, 2020$90.48M+19.1%
Q3 FY2020Sep 30, 2020$88.69M+34.9%
Q2 FY2020Jun 30, 2020$78.95M+23.1%
Q1 FY2020Mar 31, 2020$78.68M+42.6%
Q4 FY2019Dec 31, 2019$75.97M-4.9%
Q3 FY2019Sep 30, 2019$65.76M+6.6%
Q2 FY2019Jun 30, 2019$64.11M-4.4%
Q1 FY2019Mar 31, 2019$55.18M+5.4%
Q4 FY2018Dec 31, 2018$79.86M+14.9%
Q3 FY2018Sep 30, 2018$61.68M+26.8%
Q2 FY2018Jun 30, 2018$67.09M+14.6%
Q1 FY2018Mar 31, 2018$52.38M+29.4%
Q4 FY2017Dec 31, 2017$69.52M+59.4%
Q3 FY2017Sep 30, 2017$48.64M–
Q2 FY2017Jun 30, 2017$58.56M–
Q1 FY2017Mar 31, 2017$40.49M–
Q4 FY2016Dec 31, 2016$43.61M–

More Innoviva figures

See a number that looks wrong?